Lethal Risk Factors in Patients with Rifampicin Resistant Tuberculosis according to Federal Register of Tuberculosis Cases
https://doi.org/10.58838/2075-1230-2024-102-6-40-47
Abstract
The objective: to study the factors influencing the risk and timing of a lethal outcome in tuberculosis patients with confirmed resistance to rifampicin in general population (Federal Register of Tuberculosis Cases of the Russian Federation (FRTBC)).
Subjects and Methods. 15,604 tuberculosis patients with confirmed resistance to at least rifampicin and registered for treatment in 2021 were enrolled in a retrospective cohort study of lethal outcome predictors in general population (Federal Register of Tuberculosis Cases of the Russian Federation (FRTBC)).
Results. The leading lethal risk factors were as follows: positive HIV status (aOR=2.82; 95% CI 2.60-3.06), history of treatment interruption (aOR=1.90; 95% CI 1.67-2.15), and patient age (aOR=1.03; 95% CI 1.02-1.03). The lower risk of mortality was noted in female patients (aOR=0.76; 95% CI 0.69-0.83), patients susceptible to fluoroquinolones (aOR=0.77; 95% CI 0.71-0.85), and patients with tuberculosis relapse (aOR=0.85; 95% CI 0.75-0.97). The time to death was shorter in new tuberculosis patients, patients with no confirmed resistance to fluoroquinolone, and HIV positive patients not receiving antiretroviral therapy (ART).
Conclusion. To reduce the risk of a lethal outcome in addition to early detection of tuberculosis, it is advisable to administer antiretroviral therapy in HIV positive patients in a timely manner, as well as to monitor the adequacy of anti-tuberculosis therapy prescribed and the patient's adherence to treatment.
About the Authors
I. A. Vasilyeva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Irina A. Vasilyeva - Doctor of Medical Sciences, Professor, Director
Build. 2, 4 Dostoevskiy St., Moscow, 127473
Phone: +7 (495) 681-11-66
V. V. Testov
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Vadim V. Testov - Candidate of Medical Sciences, Deputy Director for Statistics and Reporting
Build. 2, 4 Dostoevskiy St., Moscow, 127473
Phone: +7 (495) 681-11-66
S. A. Sterlikov
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; Russian Medical Academy of On-going Professional Education, Russian Ministry of Health
Russian Federation
Russian Federation
Sergey A. Sterlikov - Doctor of Medical Sciences, Head of Department for Tuberculosis and HIV Epidemiology and Monitoring, Head of Department of Medical Statistics and Digital Health Care, Russian Medical Academy of On-going Professional Education, Russian Ministry of Health
Build. 2, 4 Dostoevskiy St., Moscow, 127473
Phone: +7 (495) 681-11-66
V. S. Burykhin
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Valery S. Burykhin - Physician Responsible for Statistics and Reporting, Center of Socially Important Infections
Build. 2, 4 Dostoevskiy St., Moscow, 127473
Phone: +7 (495) 681-11-66
V. G. Kudrina
Russian Medical Academy of On-going Professional Education, Russian Ministry of Health
Russian Federation
Russian Federation
Valentina G. Kudrina - Doctor of Medical Sciences, Professor, Head of Department of Medical Statistics and Digital Health Care
2 Build. 1. Barrikadnaya St., Moscow, 125993
Phone: +7 (495) 680-05-99
N. D. Urushadze
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Natalia D. Urushadze - Junior Researcher of Infectious Pathology Department
Build. 2, 4 Dostoevskiy St., Moscow, 127473
Phone: +7 (495) 681-11-66
References
1. Burykhin V.S., Vasilyeva I.A., Sterlikov S.A., Testov V.V., Kudrina V.G., Urushadze N.D. Simulation of conditions and results of implementation of short-course treatment regimes in tuberculosis patients. Tuberculosis and Lung Diseases, 2023, vol. 101, no. 6 pp. 8-12. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-6-8-12
2. Burykhin V.S., Testov V.V., Sterlikov S.A. Age and gender features of primary drug resistance of Mycobacteria tuberculosis. Sovremennye Problemy Zdravookhraneniya i Meditsinskoy Statistiki, 2022, no. 3, pp. 271-286. (In Russ.) https://doi.org/10.24412/2312-2935-2022-3-271-286
3. Vasilyeva I.A., Sterlikov S.A., Testov V.V., Mikhaylova Yu.V., Obukhova O.V., Ponomarev S.B., Kudlay D.A. Otraslevye i ekonomicheskiye pokazateli protivotuberkulyoznoy raboty v 2021-2022 gg. Statisticheskiye Materialy. [Sectoral and economic rates of tuberculosis control in 2017-2018. Statistic materials]. Moscow, FGBU NMITS FPI Minzdrava Rossii Publ., 2023, 56 p.
4. Gromov A.V., Sterlikov S.A., Mikhaylova Yu.V. Risk factors of lethal outcomes of tuberculosis in a region with low population density (Kamchatskiy Kray). Tuberculosis and Lung Diseases, 2022, vol. 100, no. 11, pp. 48-55. (In Russ.)
5. Saenko S.S. Sovershenstvovaniye organizatsii lecheniya bolnykh tuberkulezom v sovremennykh usloviyakh. Avtoref. dis. kand. med. nauk. [Improvement of organization of treatment of tuberculosis patients under current conditions. Synops. of Cand. Diss.]. Moscow, 2021, 24 p.
6. Sterlikov S.A., Galkin V.B., Maliev B.M., Shirokova A.A., Khorotetto V.A., Mayzhegisheva A.S. Impact of active case finding on treatment outcomes in adult pulmonary tuberculosis patients. Tuberculosis and Lung Diseases, 2021, vol. 99, no. 7, pp. 33-40. (In Russ.) https://doi.org/10.21292/2075-1230-2021-99-7-33-40
7. Testov V.V., Sterlikov S.A., Vasilyeva I.A., Sidorova I.A., Mikhaylova Yu.V. Federal Register of TB Cases as a tool for monitoring the impact of COVID-19 pandemic response activities on the TB care system. Tuberculosis and Lung Diseases, 2020, no. 11, pp. 6-11. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-11-6-11
8. Dale K., Tay E., Trauer J.M., Trevan P., Denholm J. Gender differences in tuberculosis diagnosis, treatment and outcomes in Victoria, Australia, 2002–2015. The International Journal Tuberculosis and Lung Diseases, 2017, vol. 21. no. 12, pp. 1264-1271. https://doi.org/10.5588/ijtld.17.0338
9. Dewan P.K., Argun P.M., Kiryanova H., Kondroshova N.V., Khorosheva T.M., Laserson K., Kluge H., Jakubowiak W., Wells C., Kazionny B. Risk factors for death during tuberculosis treatment in Orel, Russia. The International Journal Tuberculosis and Lung Diseases, 2004, vol. 8, no. 5, pp. 598-602.
10. Gayoso R., Dalcolmo M., Braga J.U., Barreira D. Predictors of mortality in multidrug-resistant tuberculosis patients from Brazilian reference centers, 2005 to 2012. Braz. J. Infect. Dis., 2018, vol. 22, no. 4, pp. 305-310. https://doi.org/10.1016/j.bjid.2018.07.002
11. Hood G., Trieu L., Ahuja S.D. Mortality among tuberculosis patients in New York City. The International Journal Tuberculosis and Lung Diseases, 2019, vol. 23, no. 2, pp. 252-259. https://doi.org/10.5588/ijtld.18.0305
12. Kliiman K., Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. The International Journal Tuberculosis and Lung Diseases, 2010, vol. 14, no. 4, pp. 454-463.
13. Nair D., Velayutham B., Kannan T., Tripathy J.P., Harries A.D., Natrajan M., Swaminathan S. Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. Public Health Action, 2017, vol. 7, no. 1, pp. 32-38. https://doi.org/10.5588/pha.16.0055
14. Orofino R.L., Brasil P.E., Trajman A., Schmaltz C.A.S., Dalcolmo M., Rolla V.C. Predictors of tuberculosis treatment outcomes. J. Bras. Pneumol., 2012, vol. 38, no. 1, pp. 88-97. https://doi.org/10.1590/S1806-37132012000100013
15. Tuberculosis surveillance and monitoring in Europe 2023: 2021 data. World Health Organization and the European Centre for Disease Prevention and Control, 2023. 145 p.
Review
For citations:
Vasilyeva I.A., Testov V.V., Sterlikov S.A., Burykhin V.S., Kudrina V.G., Urushadze N.D. Lethal Risk Factors in Patients with Rifampicin Resistant Tuberculosis according to Federal Register of Tuberculosis Cases. Tuberculosis and Lung Diseases. 2024;102(6):40-47. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-6-40-47
Views:
320
Email this article 